Table 1.
Baseline characteristics.
| Level | Trials with low accrual (n = 145) | Trials with successful accrual (n = 152) | P | |
|---|---|---|---|---|
| Sponsor type | Industrial | 35 (31.0) | 78 (69.0) | <0.001 |
| Institutional | 43 (58.1) | 31 (41.9) | ||
| National | 58 (65.9) | 30 (34.1) | ||
| Other Externally Peer Reviewed | 9 (40.9) | 13 (59.1) | ||
| Trial phase | I | 23 (34.3) | 44 (65.7) | 0.042 |
| I/II | 5 (29.4) | 12 (70.6) | ||
| II | 31 (52.5) | 28 (47.5) | ||
| III | 40 (56.3) | 31 (43.7) | ||
| Pilot | 7 (53.8) | 6 (46.2) | ||
| Disease category | Breast | 11 (42.3) | 15 (57.7) | <0.001 |
| Gastrointestinal | 15 (57.7) | 11 (42.3) | ||
| Genitourinary | 22 (46.8) | 25 (53.2) | ||
| Head & Neck | 7 (53.8) | 6 (46.2) | ||
| Hematopoietic Malignancies | 8 (47.1) | 9 (52.9) | ||
| Neuro-Oncology | 5 (35.7) | 9 (64.3) | ||
| Pediatrics | 40 (80.0) | 10 (20.0) | ||
| Phase I | 22 (32.8) | 45 (67.2) | ||
| Special Populations | 9 (60.0) | 6 (40.0) | ||
| Thoracic | 6 (40.0) | 9 (60.0) | ||
| Authored by PI | No | 117 (50.2) | 116 (49.8) | 0.438 |
| Yes | 28 (43.8) | 36 (56.2) | ||
| Clinical research | Ancillary/Correlative | 19 (82.6) | 4 (17.4) | 0.002 |
| Observational | 20 (52.6) | 18 (47.4) | ||
| Intervention | 106 (44.9) | 130 (55.1) | ||
| Multi center trial | No | 30 (46.9) | 34 (53.1) | 0.858 |
| Yes | 114 (49.1) | 118 (50.9) | ||
| Intervention modality | Drug or biological | 80 (42.8) | 107 (57.2) | 0.044 |
| Radiotherapy | 4 (44.4) | 5 (55.6) | ||
| Multimodality | 15 (71.4) | 6 (28.6) | ||
| Metastatic | No | 36 (40.9) | 52 (59.1) | 0.013 |
| No or Yes | 9 (42.9) | 12 (57.1) | ||
| Yes | 41 (60.3) | 27 (39.7) | ||
| No and Yes | 2 (16.7) | 10 (83.3) | ||
| Disease Type | Hematologic cancers | 18 (51.4) | 17 (48.6) | 0.276 |
| All cancers | 11 (45.8) | 13 (54.2) | ||
| Prostate, Colon, Lung or Breast cancers | 29 (46.8) | 33 (53.2) | ||
| All Solid Cancers | 14 (33.3) | 28 (66.7) | ||
| All Other Solid Cancers | 48 (53.9) | 41 (46.1) | ||
| Randomized | No | 56 (52.8) | 50 (47.2) | 0.110 |
| Yes | 54 (41.5) | 76 (58.5) | ||
| Placebo | No | 15 (45.5) | 18 (54.5) | 1.000 |
| Yes | 88 (44.9) | 108 (55.1) | ||
| Number of interventions | One | 45 (38.8) | 71 (61.2) | 0.055 |
| More than One | 62 (52.1) | 57 (47.9) | ||
| Multiple cancers treated | No | 33 (41.2) | 47 (58.8) | 0.230 |
| Yes | 86 (50.3) | 85 (49.7) | ||
| Rare cancer | No | 23 (57.5) | 17 (42.5) | 0.205 |
| Yes | 91 (45.0) | 111 (55.0) | ||
| New investigational agents | No | 45 (36.9) | 77 (63.1) | 0.008 |
| Yes | 56 (55.4) | 45 (44.6) | ||
| Percent Hispanic | N | 80 | 121 | 0.044 |
| Mean ± SD | 53.74 ± 25.98 | 46.85 ± 21.8 | ||
| Median [Q1, Q3] | 52.62 [36.27, 72.73] | 44.44 [33.33, 60] | ||
| Min, Max | 0, 100 | 0, 100 | ||